Recombinant Human CRACC/SLAMF7 His-tag Avi-tag Protein, CF

Biotinylated Recombinant Human CRACC/SLAMF7 His-tag Protein (Catalog # AVI11533) binds Human CRACC/SLAMF7 Antibody (MAB19061) with an ED50 of 5.00-60.0 ng/mL.

2 μg/lane of Biotinylated Recombinant Human CRACC/SLAMF7 His-tag Protein (Catalog # AVI11533) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 44-52 kDa, under reducing conditions.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human CRACC/SLAMF7 His-tag Avi-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. Biotinylated Recombinant Human CRACC/SLAMF7 His-tag (Catalog # AVI11533) binds Human CRACC/SLAMF7 Antibody (Catalog # MAB19061) with an ED₅₀ of 5.00-60.0 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human CRACC/SLAMF7 protein
  Ser23-Met226, With a C-terminal 6-His tag & Avi-tag
• Accession #: Q9NQ25.1
• N-terminal Sequence: Ser 23
• Structure / Form:

  Biotinylated via Avi-tag

• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 25 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 44-52 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CRACC/SLAMF7 His-tag Avi-tag Protein, CF

• 19A
• CD2 subset 1
• CD2-like receptor activating cytotoxic cells
• CD319 antigen
• CD319
• CRACC
• CRACCCD2-like receptor-activating cytotoxic cells
• CS119A24 protein
• Membrane protein FOAP-12
• novel LY9 (lymphocyte antigen 9) like protein
• Novel Ly9
• Protein 19A
• SLAM family member 7
• SLAMF7

Background

CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family (1). Mature human CRACC consists of an extracellular domain (ECD) with one Ig-like V-set domain and one Ig-like C2-set domain, a transmembrane segment, and a cytoplasmic domain with one immunoreceptor tyrosine-based switch motif (ITSM) (2, 3). Within the ECD, human CRACC shares 54% and 52% amino acid sequence identity with mouse and rat CRACC, respectively. There are seven known isoforms of CRACC which are distinguished by deletions and/or substitutions in both their ECD and cytoplasmic domains. CRACC is expressed on the surface of NK cells, CD8+ T cells, activated B cells, and mature dendritic cells (4, 5). Its homophilic interaction induces NK, CTL, and B cell activation (4-7). In human NK cells, activated CRACC transmits signals following association with the adaptor protein EAT-2 (8).Our Avi-tag Biotinylated Recombinant Human CRACC/SLAMF7 features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

1. Veillette, A. (2006) Immunol. Rev. 214:22.
2. Tovar, V. et al. (2002) Immunogenetics 54:394.
3. Murphy, J.J. et al. (2002) Biochem. J. 361:431.
4. Bouchon, A. et al. (2001) J. Immunol. 167:5517.
5. Lee, J.K. et al. (2007) J. Immunol. 179:4672.
6. Kumaresan, P.R. et al. (2002) Mol. Immunol. 39:1.
7. Stark, S. and C. Watzl (2006) Int. Immunol. 18:241.
8. Tassi, H. and M. Colonna (2005) J. Immunol. 175:7996.

Bioinformatics

• Uniprot:
  • Q9NQ25.1()